Direct Flow Medical, Inc. Announces Fifth Patent Issuance of Their Unique Percutaneous Aortic Valve Technology
Published: May 20, 2009
SANTA ROSA, Calif.--(BUSINESS WIRE)--Direct Flow Medical, Inc. a privately held, emerging medical device Company developing a next generation, minimally invasive implant to treat patients with heart valve disease announced today the issuance of its 5th patent on their Percutaneous Aortic Valve (PAV) Technology. The patent (USP# 7,534,259) entitled: “Nonstented Heart Valves with Formed in situ Support” provides further protection for this second generation PAV device.